- Home
- MASI vs JAZZ Comparison
MASI vs JAZZ Comparison
Compare MASI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASI
- JAZZ
- Stock Information
- Founded
- MASI 1989
- JAZZ 2003
- Country
- MASI United States
- JAZZ Ireland
- Employees
- MASI N/A
- JAZZ N/A
- Industry
- MASI Medical/Dental Instruments
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- MASI Health Care
- JAZZ Health Care
- Exchange
- MASI Nasdaq
- JAZZ Nasdaq
- Market Cap
- MASI 8.2B
- JAZZ 6.7B
- IPO Year
- MASI 2007
- JAZZ 2007
- Fundamental
- Price
- MASI $165.66
- JAZZ $111.55
- Analyst Decision
- MASI Buy
- JAZZ Strong Buy
- Analyst Count
- MASI 6
- JAZZ 12
- Target Price
- MASI $187.00
- JAZZ $183.08
- AVG Volume (30 Days)
- MASI 583.8K
- JAZZ 674.9K
- Earning Date
- MASI 08-05-2025
- JAZZ 07-30-2025
- Dividend Yield
- MASI N/A
- JAZZ N/A
- EPS Growth
- MASI N/A
- JAZZ 49.21
- EPS
- MASI N/A
- JAZZ 7.51
- Revenue
- MASI $2,126,800,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- MASI N/A
- JAZZ $6.05
- Revenue Next Year
- MASI $7.74
- JAZZ $4.68
- P/E Ratio
- MASI N/A
- JAZZ $14.87
- Revenue Growth
- MASI 16.68
- JAZZ 5.76
- 52 Week Low
- MASI $101.61
- JAZZ $95.49
- 52 Week High
- MASI $194.88
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- MASI 49.72
- JAZZ 54.01
- Support Level
- MASI $161.18
- JAZZ $107.17
- Resistance Level
- MASI $172.55
- JAZZ $111.51
- Average True Range (ATR)
- MASI 4.93
- JAZZ 2.57
- MACD
- MASI -0.71
- JAZZ 0.25
- Stochastic Oscillator
- MASI 39.58
- JAZZ 79.17
About MASI Masimo Corporation
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.